Implantica (IMP) Q2 2024 earnings summary

Executive summary

• Focused on commercializing RefluxStop™, a novel implant for acid reflux, with strong clinical and market momentum and superior clinical outcomes and cost-effectiveness.

• Building a robust e-health platform and pipeline, but resources are currently concentrated on RefluxStop™.

• Net sales rose 59% year-over-year in Q2 to €554k and 75% for H1 to €1.15m, driven by RefluxStop™ adoption among key European centers.

• Operating loss (EBIT) increased to €5.87m in Q2 and €12.96m for H1, mainly due to higher R&D costs related to FDA submissions.

• Regulatory progress includes completion of FDA PMA Module I review with only minor findings and ongoing NICE IPAC evaluation in the UK.

Financial highlights

• Q2 2024 net sales reached €554,000, up 59% year-over-year; H1 net sales €1.15m, up 75%.

• Adjusted gross margin was 91% in Q2 and H1, slightly down from 94% last year.

• Q2 operating loss (EBIT): €5.87m (vs. €4.28m prior year); H1 operating loss: €12.96m (vs. €9.15m prior year).

• Net cash outflow was €6.54m in Q2; cash balance at quarter-end was €74m, with no interest-bearing debt.

• Basic and diluted loss per Class A share: €0.09 in Q2, €0.14 for H1.

Outlook and guidance

• Near-term focus on FDA approval, with Module 2 filing imminent and approval expected in 2024 or 2025, depending on FDA site visits.

• Anticipates NICE decision in H1 2025, which could significantly impact UK reimbursement and adoption.

• US market launch of RefluxStop™ targeted at 20-30 leading centers, pending FDA approval.

• Liquidity remains strong with €74 million in cash and short-term investments as of June 30, 2024; no interest-bearing debt.

• Plans to expand in the US and Japan post-approval, leveraging existing clinical data to accelerate market entry.